Adding Hormone Therapy to Brachytherapy May Raise Death Risk in Older Men
Adding androgen deprivation therapy (ADT) to brachytherapy for localized prostate cancer may increase the risk of death among men aged 73 years and older, data suggest.
Diagnosis & Disease Information
Fractures Increase Mortality Risk In Prostate Cancer Patients on ADT
BERLIN—Men with non-metastatic prostate cancer who begin androgen deprivation therapy (ADT) with vertebral fractures at baseline have shorter survival time compared with those free of baseline fractures.
Drug Raises Bone Mineral Density in ADT Recipients
In a study of prostate cancer patients, denosumab also decreased the risk of new vertebral fractures.
Urine Test May Predict Aggressive PCa
ORLANDO—A urine test may enable clinicians to predict which men diagnosed with prostate cancer are more likely to have aggressive disease and which men might benefit most from androgen deprivation therapy (ADT).
New Nomograms May Help Guide ADT Use
BOSTON—Researchers have developed two nomograms that use patients’ clinical information to estimate the benefit of adding androgen deprivation therapy (ADT) to radiation therapy.
Age Alone Should Not Deter ADT Use
BOSTON—Age alone should not matter when deciding whether to combine long-term androgen deprivation therapy (ADT) and radiation therapy in men with high-risk prostate cancer, a study found.
Zoledronic Acid Benefits Confirmed
STOCKHOLM—Treatment with zoledronic acid for two years in men who are undergoing androgen deprivation therapy (ADT) for prostate cancer is usually well tolerated and effective for preventing bone loss, new findings suggest.
ADT-Related Anxiety Linked to Elevated PSA
Men with elevated serum PSA levels prior to beginning androgen deprivation therapy (ADT) for prostate cancer are nearly eight times more likely to experience anxiety after starting ADT, researchers reported.
Testosterone Affects Survival in Advanced PCa
The lower the testosterone level achieved in men undergoing androgen deprivation therapy (ADT) for advanced prostate cancer, the better their chances of survival, an Italian study found.
Epilepsy Drug Eases the Hot Flashes of ADT
Gabapentin (Neurontin) may provide a safe and effective treatment for hot flashes in men receiving androgen deprivation therapy (ADT) for prostate cancer.
- Loading...
Loading...
Next post in News
Loading... 
Loading...